Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial

INTRODUCTION: EndoPredict (EP) is an RNA-based multigene test that predicts the likelihood of distant recurrence in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) breast cancer (BC) who are being treated with adjuvant endocrine therapy. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Miguel, Brase, Jan C, Calvo, Lourdes, Krappmann, Kristin, Ruiz-Borrego, Manuel, Fisch, Karin, Ruiz, Amparo, Weber, Karsten E, Munarriz, Blanca, Petry, Christoph, Rodriguez, Cesar A, Kronenwett, Ralf, Crespo, Carmen, Alba, Emilio, Carrasco, Eva, Casas, Maribel, Caballero, Rosalia, Rodriguez-Lescure, Alvaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076639/
https://www.ncbi.nlm.nih.gov/pubmed/24725534
http://dx.doi.org/10.1186/bcr3642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076639/
https://www.ncbi.nlm.nih.gov/pubmed/24725534
http://dx.doi.org/10.1186/bcr3642

Ejemplares similares